首页> 外文期刊>Antimicrobial agents and chemotherapy. >Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.
【24h】

Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.

机译:每公斤体重脂质体两性霉素B总剂量15毫克的药代动力学和颊粘膜浓度为单次剂量(15 mg / kg),每周剂量(7.5 mg / kg)或每日剂量(1 mg / kg)在外周干细胞移植患者中。

获取原文
获取原文并翻译 | 示例
           

摘要

The pharmacokinetics and safety of extended-interval dosing of prophylactic liposomal amphotericin B (L-AMB) in peripheral stem cell transplant recipients were evaluated. The patients received L-AMB daily at 1 mg/kg of body weight or weekly at 7.5 mg/kg or received L-AMB as a single dose (15 mg/kg). The buccal mucosal tissue concentrations of L-AMB were measured. Of the 24 patients enrolled, 5 withdrew after the initial dose due to an infusion-related reaction (n = 2) or significant increases in the serum creatinine (Scr) levels (n = 3). Weekly L-AMB dosing (7.5 mg/kg) produced mean plasma concentrations of >0.300 microg/ml for the first 7 days and >0.220 microg/ml for 7 days after the second dose. A single L-AMB dose (15 mg/kg) produced mean plasma concentrations of >0.491 microg/ml for at least 7 seven days. These concentrations are within the range of the MICs reported in the literature for susceptible strains of Candida and are at the lower limits of the MICs for Aspergillus spp. Extended-interval dosing produced buccal mucosal tissue concentrations well in excess of the MICs reported in the literature for susceptible strains of Candida and Aspergillus spp. Infusion-related reactions occurred in 24% of the patients. Baseline and end-of-study Scr, electrolyte (K+, Mg2+, PO4), and serum transaminase levels were similar across the dosage groups. Five (31%) patients met the nephrotoxicity definition prior to completion of the study. Patients in the weekly or single-dose groups experienced nephrotoxicity significantly faster than the patients in the daily dosing cohort. A weekly L-AMB dose (7.5 mg/kg) or a single L-AMB dose (15 mg/kg) produced sufficient concentrations in plasma and highly vascular tissue to warrant further studies of the safety, efficacy, and practicality of the weekly prophylactic administration of L-AMB.
机译:评估了预防性脂质体两性霉素B(L-AMB)在外周干细胞移植受者中延长间隔给药的药代动力学和安全性。患者每天接受1 mg / kg体重的L-AMB或每周接受7.5 mg / kg的L-AMB或单剂量(15 mg / kg)接受L-AMB。测量了L-AMB的颊粘膜组织浓度。在入组的24例患者中,有5例在初始剂量后因输注相关反应(n = 2)或血清肌酐(Scr)水平显着增加(n = 3)而退出治疗。每周一次L-AMB剂量(7.5 mg / kg)在前7天产生的平均血浆浓度> 0.300 microg / ml,在第二次给药后7天产生的平均血浆浓度> 0.220 microg / ml。单次L-AMB剂量(15 mg / kg)至少7 7天产生的平均血浆浓度> 0.491 microg / ml。这些浓度在针对念珠菌的敏感菌株的文献报道的MIC范围内,并且在曲霉属菌的MIC的下限内。延长间隔给药产生的颊粘膜组织浓度远超过文献中报道的念珠菌和曲霉菌易感菌株的MIC。与输注相关的反应发生在24%的患者中。不同剂量组的基线和研究结束时的Scr,电解质(K +,Mg2 +,PO4)和血清转氨酶水平相似。五名(31%)患者在完成研究之前达到了肾毒性定义。每周或单剂量组的患者发生肾毒性的速度明显快于每日给药组的患者。每周一次L-AMB剂量(7.5 mg / kg)或一次L-AMB剂量(15 mg / kg)可在血浆和高血管组织中产生足够的浓度,从而有必要进一步研究每周一次预防剂的安全性,有效性和实用性L-AMB的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号